

STUDIES IN PROGRESS IN 2026

- **Piramid** : CML Pediatric ITK Response According to Molecular Identification at Diagnosis

Search for a molecular signature at diagnosis of children with Chronic Myeloid Leukemia to predict response to tyrosine kinase inhibitors. Collaboration with CHU Bordeaux.

- Characteristics and outcome of children receiving allogeneic transplantation for CML
- Weight gain in children treated with Imatinib for CML
- Description of mutations listed in the international register

-**TKIRM PCML** : Resistance mutations to tyrosine kinase inhibitors in pediatric chronic myeloid leukemia

Describe the different kinase domain mutations leading to resistance to tyrosine kinase inhibitors in chronic myeloid leukemia in children in the chronic phase.

- Draw parallels between the mutations identified in children and those known to occur in adults.
- Identify risk factors to develop a resistance to tyrosine kinase inhibitors
- Analyze the different proposition therapeutic and their outcomes in terms of survival

- **ISE CML-PED** : Imatinib Side Effects in Children with Chronic Myeloid Leukemia (CML) in the Chronic Phase : A French Cohort Study.

To identify the side effects of Imatinib, a first-generation tyrosine kinase inhibitor, in French children with chronic myeloid leukemia in the chronic phase registered in the EDS I-CML-Ped.

- Describe the epidemiological data for CML in children : age, sex, and disease status according to the European Leukemia Net (ELN).
- Classify adverse events, regardless of their relationship to treatment.
- Classify adverse events, whatever of their relationship to the treatment
- Compare side effects with data reported in the literature.